Phase 4 Pulmonary Hypertension Trial, Recruiting NCT06715280 Sponsor: Chinese University of Hong Kong Condition: Pulmonary Hypertension
Back to Pulmonary Hypertension

Phase 4 Pulmonary Hypertension Trial, Recruiting

NCT06715280
Recruiting Phase 4

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • You have been diagnosed with a condition called CTEPH (a type of high blood pressure in the lungs caused by blood clots) and still have symptoms after having a procedure called Balloon Pulmonary Angioplasty (BPA)
  • You have been taking a stable, maximum tolerated dose of a medication called sildenafil for at least 6 weeks, either on its own or alongside other medicines for pulmonary hypertension
  • Your doctor has rated your symptoms as WHO Functional Class III, meaning your condition noticeably limits your physical activity
  • If you take water tablets (diuretics), your dose has been stable for at least 30 days before joining the trial
  • You have not been hospitalised due to pulmonary hypertension or heart failure in the last 30 days

Who may not be able to join:

  • You have previously been treated with a drug called riociguat or similar medicines (called sGCs), or have had a serious reaction or intolerance to this type of medicine
  • You have used nitrate-based medicines (such as nitroglycerin or similar drugs) in any form within the last 30 days
  • You are pregnant, breastfeeding, or are able to become pregnant but are not using two effective forms of contraception throughout the study
  • Your kidneys are not working well enough, based on a specific measurement of kidney function falling below a certain level (confirm with trial site)
  • You have a severe level of liver disease, known as Child-Pugh C (confirm with trial site)

⚠️ Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 27 July 2026
Phase 4 trials study a drug that has already been approved, monitoring long-term safety and effectiveness in real-world use.

Contact this trial

Phone: +85235051518

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 4
Registry
ClinicalTrials.gov
Start date
25 July 2024
Est. completion
22 July 2026

Where this trial is recruiting

Hong Kong

Primary endpoints

Change in mean pulmonary artery pressure (mPAP); Change in pulmonary vascular resistance (PVR)

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 27 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov